22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire: 22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA; Details available at www.clinicaltrials.gov

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire: （ビジネスワイヤ） -- PHCホールディングス株式会社（本社：東京都港区）の100%子会社である、PHC株式会社（以下「PHC」）は、このたび、保険薬局用電子薬歴システム「PharnesV-MX」を発売しましたので、お知らせします。 PharnesV-MXは、薬剤師の業務改善を目指した新しい電子薬

Shire plc : Rule 2.9 Announcement

Shire plc : Rule 2.9 Announcement

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire: ITM announced today that the U.S. FDA has accepted the Investigational New Drug Application to advance its radiopharmaceutical to a phase III trial

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire: ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that t

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire: BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve

Bonne fête des papas

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE

Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire

Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire: The global healthcare contract research and manufacturing outsourcing market is set to post a CAGR of almost 12% until 2022, according to Technavio.

DIAXONHIT DEVIENT EUROBIO SCIENTIFIC : Changement de nom adopté à l'Assemblée Générale Annuelle

DIAXONHIT DEVIENT EUROBIO SCIENTIFIC : Changement de nom adopté à l'Assemblée Générale Annuelle

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

Elite Pharmaceuticals, Inc. Announces Passing of Board Member Eugene Pfeifer

Elite Pharmaceuticals, Inc. Announces Passing of Board Member Eugene Pfeifer

FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire

FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire: Gold Standard Diagnostics, Corp. today announced the U.S. Food and Drug Administration issued a 510(k) clearance for its Borrelia burgdorferi IgG/IgM

Global Disposable Blood Bag Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 11% - ResearchAndMarkets.com | Business Wire

Global Disposable Blood Bag Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 11% - ResearchAndMarkets.com | Business Wire: The

ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire

ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire: Die ExThera Medical Corporation, ein Entwickler von Therapien für die Entfernung von Bakterien und Viren aus dem Blut, hat heute den Abschluss ihrer S

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire: Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease throug

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire: FDA Approves Merck’s KEYTRUDA for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1

Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire

Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire: Celgene Corporation (NASDAQ: CELG) anunció hoy los resultados del estudio OPTIMISMM, un ensayo clínico fase III, internacional, aleatorizado, abierto,